Taho Pharmaceuticals Ltd. (TPEX:6467)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
116.50
+1.50 (1.30%)
At close: Jul 9, 2026
Market Cap6.02B +94.0%
Revenue (ttm)5.42M +80.8%
Net Income-232.53M
EPS-4.49
Shares Out 52.37M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume128,151
Open114.00
Previous Close115.00
Day's Range111.50 - 117.50
52-Week Range45.60 - 208.50
Beta-32.00
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Taho Pharmaceuticals

Taho Pharmaceuticals Ltd., a commercial-stage pharmaceutical company, focuses on the development of drug delivery systems in transdermal and transmucosal systems in Taiwan. The company offers TAH4411 Ondansetron ODF, a selective serotonin 5HT3 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Its pipeline includes TAH3311 Apixaban oral film, which is in phase III; TAH3341, an anticoagulant apixaban ODF extended-release film, which is in preclinical stage. The company also develops TAH2211 Buprenorphine/Naloxone ... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Employees 35
Stock Exchange Taipei Exchange
Ticker Symbol 6467
Full Company Profile

Financial Performance

Financial Statements